Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
CC transcript
Appointed director
|
|
HALOZYME THERAPEUTICS, INC. (HALO)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 08/23/2023 |
4
| LaBarre Michael J. (SVP, CHIEF TECHNICAL OFFICER) has filed a Form 4 on HALOZYME THERAPEUTICS, INC.|
Txns:
| Sold 1,925 shares
@ $42.407, valued at
$81.6k
Sold 8,075 shares
@ $42.407, valued at
$342.4k
Exercised 1,925 options to buy
@ $18.41, valued at
$35.4k
Exercised 8,075 options to buy
@ $19.98, valued at
$161.3k
|
|
| 08/22/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 08/17/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 08/17/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 08/16/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 08/15/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 08/15/2023 |
4
| Daly James M (Director) has filed a Form 4 on HALOZYME THERAPEUTICS, INC.|
Txns:
| Sold 10,000 shares
@ $43.711, valued at
$437.1k
Sold 10,000 shares
@ $43.741, valued at
$437.4k
|
|
| 08/14/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 08/11/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 08/08/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/08/2023 |
8-K
| Results of Operations and Financial Condition, Financial Statements and Exhibits Interactive Data |
| 07/27/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 07/27/2023 |
4
| Torley Helen (PRESIDENT AND CEO) has filed a Form 4 on HALOZYME THERAPEUTICS, INC.|
Txns:
| Sold 10,000 shares
@ $42.796, valued at
$428k
Sold 10,000 shares
@ $42.689, valued at
$426.9k
Sold 10,000 shares
@ $43.79, valued at
$437.9k
Exercised 10,000 options to buy
@ $13.87, valued at
$138.7k
Exercised 10,000 options to buy
@ $13.87, valued at
$138.7k
Exercised 10,000 options to buy
@ $13.87, valued at
$138.7k
|
|
| 07/26/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 07/25/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 07/19/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 07/18/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 06/09/2023 |
SC 13G/A
| VANGUARD GROUP INC reports a 10.3% stake in Halozyme Therapeutics Inc. |
| 05/09/2023 |
4
| Posard Matthew L. (Director) has filed a Form 4 on HALOZYME THERAPEUTICS, INC.|
Txns:
| Granted 8,065 shares
@ $0
Granted 11,371 options to buy
@ $31, valued at
$352.5k
|
|
| 05/09/2023 |
4
| Miyashita Akiko Moni (Director) has filed a Form 4 on HALOZYME THERAPEUTICS, INC.|
Txns:
| Granted 8,065 shares
@ $0
Granted 11,371 options to buy
@ $31, valued at
$352.5k
|
|
| 05/09/2023 |
4
| MATSUI CONNIE (Director) has filed a Form 4 on HALOZYME THERAPEUTICS, INC.|
Txns:
| Granted 8,065 shares
@ $0
Granted 11,371 options to buy
@ $31, valued at
$352.5k
|
|
| 05/09/2023 |
4
| Henderson Jeffrey William (Director) has filed a Form 4 on HALOZYME THERAPEUTICS, INC.|
Txns:
| Granted 8,065 shares
@ $0
Granted 11,371 options to buy
@ $31, valued at
$352.5k
|
|
| 05/09/2023 |
4
| Duncan Barbara Gayle (Director) has filed a Form 4 on HALOZYME THERAPEUTICS, INC.|
Txns:
| Granted 8,065 shares
@ $0
Granted 11,371 options to buy
@ $31, valued at
$352.5k
|
|
| 05/09/2023 |
4
| Daly James M (Director) has filed a Form 4 on HALOZYME THERAPEUTICS, INC.|
Txns:
| Granted 8,065 shares
@ $0
Granted 11,371 options to buy
@ $31, valued at
$352.5k
|
|
| 05/09/2023 |
4
| Connaughton Bernadette (Director) has filed a Form 4 on HALOZYME THERAPEUTICS, INC.|
Txns:
| Granted 8,065 shares
@ $0
Granted 11,371 options to buy
@ $31, valued at
$352.5k
|
|
| 05/09/2023 |
4
| BIZZARI JEAN-PIERRE (Director) has filed a Form 4 on HALOZYME THERAPEUTICS, INC.|
Txns:
| Granted 8,065 shares
@ $0
Granted 11,371 options to buy
@ $31, valued at
$352.5k
|
|
| 05/09/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/09/2023 |
8-K
| Results of Operations and Financial Condition, Financial Statements and Exhibits Interactive Data |
| 05/08/2023 |
8-K
| Submission of Matters to a Vote of Security Holders Interactive Data |
| 04/19/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 04/19/2023 |
4/A
| Form 4/A - Statement of changes in beneficial ownership of securities: [Amend] |
| 04/18/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 03/24/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 03/24/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
|
|
|